The transition from scientist to business manager in a biotech/drug discovery start-up By Dr Paul Charlton The move from a successful scientific career into senior management of a high technology start-up company frequently presents a paradigm shift for the individual in the way that they must manage both… Read More
Compound Management comes of age By Ian Yates The changing role of compound management in recent years has seen an often under-valued and under-resourced function being recognised as a key part of the drug discovery process. This article examines the challenges faced by compound… Read More
Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Read More
Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs… Read More
Secondary Screening Workstations – The emergence of compact turnkey solutions that work By Dr John Comley With the launch of new workstations focused on secondary screening applications not only are we witnessing the shrinkage of laboratory automation but we are seeing the emergence of true walk-away solutions,… Read More
New Visions in Ophthalmic Drug Development By Dr Benjamin R. Yerxa, Dr Ward M. Peterson and Robin S.Whitsell Over the last 10 years we have seen the introduction of several new ‘ophthalmology only’ pharmaceutical products emerge such as Trusopt (dorzolamide, Merck) and Xalatan (latanoprost, Pharmacia). Read More
Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug… Read More
Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead… Read More
The New Blockbuster Drugs – Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in… Read More
Finding and minding R&D talent the hidden human cost of merger mania By Sue Harris This article examines the impact on R&D staff of the current economic uncertainty, the raft of mega-mergers and the growth of the biotech sector. Senior management repeatedly comment that finding, motivating and retaining… Read More
Share Share Tweet Email Stem Cell PHARMACEUTICS Stem Cell PHARMACEUTICS By Dr Gregory G. Lennon Recent research advances in the understanding of stem cell properties are inevitably leading to therapeutic strategies potentially applicable to… Read More
Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the… Read More
Protein Biochips – On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. Read More
CNS Drug Discovery – Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Read More
By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in particular has been the target of a number of cost-cutting exercises by governments and payers aimed… Read More
Proteomatics – New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics. Read More
